4030-A COMPARISON OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Moon Haeng Hur 1 , Youngsu Park 1 , Yunmi Ko 1 , Hyunjae Shin 1 , Jeayeon Park 1 , Ju Yeon Kim 1 , Yun Bin Lee 1 , Su Jong Yu 1 , Yoon Jun Kim 2 , Jung-Hwan Yoon 1 and Jeong-Hoon Lee 3 , (1)Seoul National University College of Medicine, (2)Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea, (3)Seoul National University College of Medicine, Seoul, South Korea Background : Recently, several novel systemic therapies and their combinations have shown favorable outcomes in patients with advanced hepatocellular carcinoma (HCC)
Increased levels of NAPQI reduce the ability to detoxify a host of toxic chemicals in the environment, increasing oxidative stress, which leads to protein, lipid, and nucleic acid damage from free radicals
Glutathione injections are generally well tolerated
Electrochemical evaluation of the interaction between ascorbic acid and the cardiotonic drug RS-82856
20 DixonD
